Cabergoline for Endometriosis

"Cabergoline 0.5 MG is a well-known medicine used to suppress lactation, as well as for treating pituitary adenoma and idiopathic hyperprolactinemic disorder remedies."

"Considering the Phase 2 trial status of Cabergoline 0.5 MG, our team at Power assessed its safety as a score of 2 since there is only limited clinical data to prove efficacy but some demonstrating security."

"Indeed, clinicaltrials.gov confirms that this medical research is actively enrolling participants since it was first listed on December 2nd 2019. 80 patients will be recruited from two different centres and the information has been recently updated as of September 15th 2022."

"Affirmative, information hosted on clinicaltrials.gov illustrates that this medical trial is actively seeking out new candidates; it was first posted on December 2nd 2019, and has been updating since September 15th 2022. Currently the study requires 80 participants from two separate sites to enrol in the experiment."

"This study necessitates that potential participants be between 15 and 40 years of age."

"This research seeks to recruit 80 individuals with endometrioma within the age range of 15-40 years. Moreover, participants must have been using hormonal therapy for at least two months prior, be able to prove a diagnosis of endometriosis through surgery, report pelvic pain on Visual Analog Scale that is equal or higher than 3 out of 10 for at least 14 days in the 2 months before enrollment and agree to follow study guidelines."

"At present, six Cabergoline 0.5 MG trials are ongoing in 41 cities and 30 countries around the world. The initial clinical trial for this drug was funded by RECORDATI GROUP in 2013; it had a sample size of 413 participants and accomplished Phase 4 approval. In total, 43 studies have been conducted since then."

"The primary metric of the study, which will be assessed every 6 weeks for 6 months, is a change in pain severity as evaluated by Visual Analog Scale (VAS). Additionally, secondary outcomes include incidence of vaginal bleeding over a half-year period and changes in serum concentrations of high sensitivity C-reactive protein, interleukins 1B and 8, tumor necrosis factor alpha ,and vascular endothelial growth factor. Finally, central hypersensitization can be measured via quantitative sensory testing at the abdomen."